Sponsors (2)
Official title: Amend the Fentanyl Sanctions Act to address trafficking of copy-cat and counterfeit drugs and active pharmaceutical ingredients, and for other purposes.
Introduced November 6, 2025 by Thomas Bryant Cotton · Last progress November 6, 2025
The bill broadens U.S. authority and statutory coverage to address a wider range of illicit drugs and counterfeit/copy‑cat ingredients—potentially improving public health protection and enforcement flexibility—while increasing regulatory reach, compliance costs, potential justice impacts, and reducing some transparency and oversight.
Patients and the public face lower risk from dangerous fake medicines because the law explicitly covers counterfeit drugs and 'copy‑cat' ingredients, reducing availability of adulterated or low‑quality products.
Federal law enforcement and sanctions authorities can target a wider set of illicit drugs (including synthetics and emerging analogs), enabling more comprehensive counternarcotics and sanctions actions.
Clarifying or preserving a Presidential waiver for medication access helps ensure patients (including Medicaid and Medicare beneficiaries) can continue obtaining necessary prescription medicines during supply or sanction-related disruptions.
Manufacturers, ingredient suppliers, and legitimate distributors face broader enforcement exposure and compliance costs because the 'copy‑cat' definition can reach products made by different processes or with different purity, creating risk of recalls, liability, and higher regulatory burden.
Expanding coverage from 'opioids' to all 'illicit drugs' increases the chance that a wider set of supply‑chain actors (including small suppliers and foreign entities) will be investigated, sanctioned, or prosecuted, broadening justice‑system impacts.
Removing required DNI reporting and enabling delegation reduces formal congressional oversight and transparency of counternarcotics intelligence activities, diluting accountability for how authorities are used.
Based on analysis of 5 sections of legislative text.
Broadens fentanyl‑focused sanctions law to cover all "illicit drugs," adds "copy‑cat ingredients" and "counterfeit drugs," and changes DNI authority and reporting rules.
Broadens the Fentanyl Sanctions Act from opioid-specific language to cover a wider class of “illicit drugs,” adds new definitions for “copy‑cat ingredients” and explicitly includes “counterfeit drugs,” and makes changes to delegation, program scope, and reporting requirements for the Director of National Intelligence. It also updates cross‑references and replaces opioid‑specific terms across related statutory provisions with generic “illicit drug” language. These edits expand covered substances and change certain program authorities and reporting duties, and one insertion affecting a Presidential waiver for prescription medication access could alter waiver conditions (text not shown).